 |
 |

Heart-Lung Transplantation for Patients With Cystic FibrosisA Test of Clinical Wisdom
Stanley B. Fiel, MD
Arch Intern Med. 1991;151(5):870-872.
 |
 |
| Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings. |
|
 |
 |
It is becoming increasingly clear that scientific or technologic advance in medicine (as in other fields) has the effect of multiplying ethical choices or, from a somewhat different perspective, of heaping new burdens of nuanced judgment on already overburdened clinicians. This is more evident, and more dramatic, in acute than in chronic illness; in the latter, the therapeutic status quo is rarely upset by major breakthroughs. Heart-lung transplantation (HLT) in end-stage cystic fibrosis (CF), however, is an example of what now may provisionally be called a therapeutic breakthrough in a chronic disease, in view of the apparent fact that the transplanted lungs do not redevelop CF.
Since the early 1980s, when the first CF HLTs were performed, with encouraging results, clinicians dealing with patients with end-stage CF have been faced with the need to make judgments regarding which patients to recommend as candidates for HLT. The scope of ethical choice
. . . [Full Text PDF of this Article]
Author Affiliations
Temple University Hospital Pulmonary and Critical Care Section 3401 N Broad St Philadelphia, PA 19140
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
|